News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Exyn Technologies Partners with Measur to Expand Canadian Footprint
Measur plans to bring Exyn's cutting-edge technologies like the Nexys 3D SLAM LiDAR payload system to market.
Cogwear to Open New Manufacturing Facility in St. Paul as it Continues to Expand
This new site will support the production of Cogwear’s second-generation brain-tracking headband, which offers real-time insights into various brain functions.
EnaChip Leverages Magnetics to PowerNext-Generation Microdevices
By electroplating specialized magnetic alloys directly onto semiconductor substrates, EnaChip offers innovative, high-performance, and cost-effective magnetic solutions.
Ascidian Therapeutics Announces First-Ever FDA approval of their Investigational New Drug (IND) ACDN-01, which Targets Rare Genetic Eye Diseases
Penn spinout Ascidian Therapeutics has achieved a significant milestone with the FDA's acceptance of their Investigational New Drug (IND) application for ACDN-01.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Achieves FDA Clearance for Phase I Trial of its CAR T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iECURE Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
Penn Startups Recognized in Labiotech’s List of “Eight companies spearheading Philadelphia’s biotech industry”
After emerging from stealth mode in 2023, BlueWhale aims to develop a technology platform and product portfolio that will provide the benefits of cell therapy to patients more quickly.
The Chamber of Commerce for Greater Philadelphia Recognizes the Philadelphia Region as Leader in Cell and Gene Therapy
The report highlights Penn’s significant contributions to the growth of the CGT sector in Greater Philadelphia, including spinning out over 40 CGT companies since 2018.